However, the genetic analysis carried out in subjects at risk of developing the NASH disease but who do not yet show clinical signs has not yet given certain data regarding a possible alteration of the gene that synthesizes IL-23, and the candidacy of the IL-17/IL-23 axis in NASH is yet to be fully established. The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatohepatitis.